

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version 14.0 Revision Date: 11/20/2025 SDS Number: 58636-00031 Date of last issue: 06/16/2025
Date of first issue: 02/16/2015

SECTION 1. IDENTIFICATION

Product name : Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Hazards for the product as supplied

Eye irritation : Category 2A
Reproductive toxicity : Category 2
Specific target organ toxicity : Category 2 (Blood, Bone, Kidney)
- repeated exposure (Oral)

Other hazards

None known.

Hazards associated with a change in physical form:

Conditions	Hazards
If small particles are generated during further processing, handling or by other means.	May form combustible dust concentrations in air.

GHS label elements

Hazard pictograms :

Signal Word : Warning

Hazard Statements : H319 Causes serious eye irritation.
H361D Suspected of damaging the unborn child.
H373 May cause damage to organs (Blood, Bone, Kidney)

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version 14.0 Revision Date: 11/20/2025 SDS Number: 58636-00031 Date of last issue: 06/16/2025
Date of first issue: 02/16/2015

through prolonged or repeated exposure if swallowed.

Precautionary Statements :

Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P313 IF exposed or concerned: Get medical attention.
P337 + P313 If eye irritation persists: Get medical attention.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS No./Unique ID	Concentration (% w/w)	Trade secret
Cellulose	9004-34-6*	>= 10 - <= 30	TSC
Lamivudine	134678-17-4*	>= 10 - <= 30	TSC
Tenofovir	202138-50-9*	>= 10 - <= 30	TSC
Doravirine	1338225-97-0*	>= 5 - <= 10	TSC

* Indicates that the identifier is a CAS No.

TSC- the actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version 14.0	Revision Date: 11/20/2025	SDS Number: 58636-00031	Date of last issue: 06/16/2025 Date of first issue: 02/16/2015
-----------------	------------------------------	----------------------------	---

In case of skin contact	: Get medical attention. In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse.
In case of eye contact	: Thoroughly clean shoes before reuse. In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: Causes serious eye irritation. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure if swallowed.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	: Carbon oxides Nitrogen oxides (NO _x) Halogenated compounds Metal oxides
Specific extinguishing meth- ods	: Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/16/2025
14.0	11/20/2025	58636-00031	Date of first issue: 02/16/2015

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.
Store locked up.
Store in accordance with the particular national regulations.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version 14.0 Revision Date: 11/20/2025 SDS Number: 58636-00031 Date of last issue: 06/16/2025
Date of first issue: 02/16/2015

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

inert or nuisance dust	50 Million particles per cubic foot Value type (Form of exposure): TWA (total dust) Basis: OSHA Z-3
	15 mg/m ³ Value type (Form of exposure): TWA (total dust) Basis: OSHA Z-3
	5 mg/m ³ Value type (Form of exposure): TWA (respirable fraction) Basis: OSHA Z-3
	15 Million particles per cubic foot Value type (Form of exposure): TWA (respirable fraction) Basis: OSHA Z-3
Dust, nuisance dust and particulates	10 mg/m ³ Value type (Form of exposure): PEL (Total dust) Basis: CAL PEL
	5 mg/m ³ Value type (Form of exposure): PEL (respirable dust fraction) Basis: CAL PEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
		TWA (Respirable)	5 mg/m ³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m ³	OSHA Z-1
Lamivudine	134678-17-4	TWA	100 µg/m ³ (OEB 2)	Internal
Tenofovir	202138-50-9	TWA	150 µg/m ³ (OEB 2)	Internal
Doravirine	1338225-97-0	TWA	500 µg/m ³ (OEB2)	Internal

Engineering measures : Use feasible engineering controls to minimize exposure to compound.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version 14.0	Revision Date: 11/20/2025	SDS Number: 58636-00031	Date of last issue: 06/16/2025 Date of first issue: 02/16/2015
-----------------	------------------------------	----------------------------	---

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

- Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.
- Hand protection
Material : Chemical-resistant gloves
- Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection : Work uniform or laboratory coat.
Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- Appearance : powder
- Color : No data available
- Odor : No data available
- Odor Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version 14.0	Revision Date: 11/20/2025	SDS Number: 58636-00031	Date of last issue: 06/16/2025 Date of first issue: 02/16/2015
-----------------	------------------------------	----------------------------	---

Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	Not applicable
Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics Particle size	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
------------	---	--

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/16/2025
14.0	11/20/2025	58636-00031	Date of first issue: 02/16/2015

Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	:	Acute toxicity estimate: 2,604 mg/kg Method: Calculation method
---------------------	---	--

Components:

Cellulose:

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg

Lamivudine:

Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg LD50 (Mouse): 4,000 mg/kg Remarks: No mortality observed at this dose.
Acute toxicity (other routes of administration)	:	LD50 (Rat): > 2,000 mg/kg Application Route: Intravenous

Tenofovir:

Acute oral toxicity	:	LD50 (Rat): > 1,500 mg/kg LD50 (Dog): 30 mg/kg
---------------------	---	---

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/16/2025
14.0	11/20/2025	58636-00031	Date of first issue: 02/16/2015

||

Doravirine:

Acute oral toxicity : LD50 (Rat): > 750 mg/kg
Remarks: No mortality observed at this dose.

(Rat): Method: Phototoxicity
Remarks: No evidence of phototoxicity was observed

LD50 (Dog): > 1,000 mg/kg
Remarks: No mortality observed at this dose.

LD50 (Mouse): > 450 mg/kg
Remarks: No mortality observed at this dose.

Skin corrosion/irritation

Not classified based on available information.

Components:

Lamivudine:

Species : Rabbit
Result : Mild skin irritation

Tenofovir:

Species : Rabbit
Result : Mild skin irritation

Doravirine:

Remarks : No data available

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

Lamivudine:

Species : Rabbit
Result : No eye irritation

Tenofovir:

Species : Rabbit
Result : Severe irritation

Doravirine:

Remarks : No data available

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/16/2025
14.0	11/20/2025	58636-00031	Date of first issue: 02/16/2015

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Lamivudine:

Routes of exposure	:	Dermal
Species	:	Guinea pig
Result	:	Not a skin sensitizer.

Tenofovir:

Test Type	:	Maximization Test
Routes of exposure	:	Skin contact
Species	:	Guinea pig
Result	:	Not a skin sensitizer.

Doravirine:

Remarks	:	No data available
---------	---	-------------------

Germ cell mutagenicity

Not classified based on available information.

Components:

Cellulose:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative

Lamivudine:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Mouse Lymphoma Result: equivocal
-----------------------	---	--

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/16/2025
14.0	11/20/2025	58636-00031	Date of first issue: 02/16/2015

Genotoxicity in vivo	: Test Type: Micronucleus test Species: Rat Application Route: Oral Result: negative Test Type: Unscheduled DNA synthesis (UDS) test with mammalian liver cells in vivo Species: Rat Result: negative
----------------------	--

Tenofovir:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: equivocal Test Type: In vitro mammalian cell gene mutation test Result: positive
Genotoxicity in vivo	: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Mouse Application Route: Intraperitoneal injection Result: negative
Germ cell mutagenicity - Assessment	: Weight of evidence does not support classification as a germ cell mutagen.

Doravirine:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: negative
Genotoxicity in vivo	: Test Type: Micronucleus test Species: Rat Cell type: Bone marrow Application Route: Oral Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Cellulose:

Species	: Rat
Application Route	: Ingestion
Exposure time	: 72 weeks
Result	: negative

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/16/2025
14.0	11/20/2025	58636-00031	Date of first issue: 02/16/2015

Lamivudine:

Species	: Rat
Exposure time	: 2 Years
Result	: negative

Species	: Mouse
Exposure time	: 2 Years
Result	: negative

Tenofovir:

Species	: Mouse
Application Route	: Oral
Exposure time	: 104 weeks
Result	: negative

Species	: Rat
Application Route	: Oral
Exposure time	: 104 weeks
Result	: negative

Doravirine:

Species	: Mouse
Application Route	: Oral
Exposure time	: 6 Months
Result	: negative
Remarks	: No significant adverse effects were reported

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Cellulose:

Effects on fertility	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
----------------------	---

Effects on fetal development	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion
------------------------------	--

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version 14.0	Revision Date: 11/20/2025	SDS Number: 58636-00031	Date of last issue: 06/16/2025 Date of first issue: 02/16/2015
-----------------	------------------------------	----------------------------	---

	Result: negative
Lamivudine:	
Effects on fertility	: Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral Fertility: NOAEL: 900 mg/kg body weight Result: No effects on fertility and early embryonic development were detected.
Effects on fetal development	: Test Type: Embryo-fetal development Species: Rabbit Application Route: Oral Symptoms: Preimplantation loss., Skeletal malformations. Result: Embryotoxic effects and adverse effects on the offspring were detected. Test Type: Embryo-fetal development Species: Rat Application Route: Oral Developmental Toxicity: LOAEL: 45 mg/kg body weight Symptoms: Effects on fetal development. Result: positive
Reproductive toxicity - Assessment	: Some evidence of adverse effects on development, based on animal experiments.
Tenofovir:	
Effects on fertility	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Oral Result: No effects on fertility.
Effects on fetal development	: Test Type: Embryo-fetal development Species: Rat Application Route: Oral Result: No adverse effects. Test Type: Embryo-fetal development Species: Rabbit Result: No adverse effects.
Doravirine:	
Effects on fertility	: Test Type: Fertility Species: Rat, male and female Fertility: NOAEL: 450 mg/kg body weight Result: No effects on fertility.
Effects on fetal development	: Test Type: Embryo-fetal development Species: Rat

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/16/2025
14.0	11/20/2025	58636-00031	Date of first issue: 02/16/2015

Application Route: Oral
Developmental Toxicity: NOAEL: 450 mg/kg body weight
Result: No adverse effects.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 300 mg/kg body weight
Result: No adverse effects.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Blood, Bone, Kidney) through prolonged or repeated exposure if swallowed.

Components:

Lamivudine:

Routes of exposure	: Ingestion
Target Organs	: Blood
Assessment	: May cause damage to organs through prolonged or repeated exposure.

Tenofovir:

Target Organs	: Bone, Kidney
Assessment	: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Cellulose:

Species	: Rat
NOAEL	: >= 9,000 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days

Lamivudine:

Species	: Rat
NOAEL	: 425 mg/kg
Application Route	: Oral
Exposure time	: 6 Months
Target Organs	: Blood
Symptoms	: Gastrointestinal discomfort, Breathing difficulties, Fatality
Remarks	: Significant toxicity observed in testing

Species	: Dog
LOAEL	: 90 mg/kg

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/16/2025
14.0	11/20/2025	58636-00031	Date of first issue: 02/16/2015

Application Route	: Oral
Exposure time	: 12 Months
Target Organs	: Blood, spleen, Liver
Symptoms	: Salivation, Diarrhea, Changes in the blood count, Liver disorders, Gastrointestinal disturbance

Species	: Mouse
NOAEL	: 500 mg/kg
Application Route	: Oral
Exposure time	: 1 Months
Target Organs	: Blood

Tenofovir:

Species	: Rat
NOAEL	: 30 mg/kg
LOAEL	: 300 mg/kg
Application Route	: Oral
Exposure time	: 13 Weeks
Target Organs	: Bone

Species	: Dog
NOAEL	: 3 mg/kg
LOAEL	: ≥ 10 mg/kg
Application Route	: Oral
Exposure time	: 42 Weeks
Target Organs	: Kidney

Species	: Monkey
LOAEL	: 10 mg/kg
Application Route	: Subcutaneous
Exposure time	: 10 Months
Target Organs	: Bone

Doravirine:

Species	: Rat
NOAEL	: 450 mg/kg
Application Route	: Oral
Exposure time	: 6 Months
Remarks	: No significant adverse effects were reported

Species	: Mouse
NOAEL	: > 450 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Remarks	: No significant adverse effects were reported

Species	: Dog
NOAEL	: $> 1,000$ mg/kg
Application Route	: Oral
Exposure time	: 9 Months
Remarks	: No significant adverse effects were reported

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/16/2025
14.0	11/20/2025	58636-00031	Date of first issue: 02/16/2015

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Lamivudine:

Ingestion : Symptoms: Headache, Fatigue, Respiratory disorders, Diarrhea, Cough

Tenofovir:

Ingestion : Symptoms: Nausea, Diarrhea, Vomiting, flatulence, Headache, Rash

Doravirine:

Ingestion : Symptoms: confusion, Headache, Dizziness, Nausea, Rash, abnormal dreams, flushing, Neurological disorders, mental depression

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Lamivudine:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 97.7 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 96.9 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 96.9 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version 14.0 Revision Date: 11/20/2025 SDS Number: 58636-00031 Date of last issue: 06/16/2025
Date of first issue: 02/16/2015

Tenofovir:

- | | | |
|--|---|---|
| Toxicity to algae/aquatic plants | : | EC50 (Raphidocelis subcapitata (freshwater green alga)): 69 mg/l
End point: Growth
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Raphidocelis subcapitata (freshwater green alga)): 18 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201 |
| Toxicity to fish (Chronic toxicity) | : | NOEC (Pimephales promelas (fathead minnow)): 9 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210 |
| Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) | : | NOEC (Daphnia magna (Water flea)): 12 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211 |
| Toxicity to microorganisms | : | EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209 |

Doravirine:

- | | | |
|---|---|--|
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Americamysis): 9.1 mg/l
Exposure time: 96 h |
| Toxicity to algae/aquatic plants | : | EC50 (Pseudokirchneriella subcapitata (green algae)): > 5.8 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 5.8 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility. |
| Toxicity to fish (Chronic toxicity) | : | NOEC (Pimephales promelas (fathead minnow)): 1 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210
Remarks: No toxicity at the limit of solubility. |
| Toxicity to daphnia and other | : | NOEC (Daphnia magna (Water flea)): 0.38 mg/l |

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/16/2025
14.0	11/20/2025	58636-00031	Date of first issue: 02/16/2015

aquatic invertebrates (Chronic toxicity)
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Lamivudine:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 4 %
Exposure time: 28 d

Tenofovir:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 3.66 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Doravirine:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 2 %
Exposure time: 28 d

Bioaccumulative potential

Components:

Lamivudine:

Partition coefficient: n-octanol/water : log Pow: -1.44

Tenofovir:

Partition coefficient: n-octanol/water : log Pow: 1.06
pH: 7

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version 14.0	Revision Date: 11/20/2025	SDS Number: 58636-00031	Date of last issue: 06/16/2025 Date of first issue: 02/16/2015
-----------------	------------------------------	----------------------------	---

Doravirine:

Partition coefficient: n-octanol/water : log Pow: 2.08

Mobility in soil

Components:

Lamivudine:

Distribution among environmental compartments : log Koc: 2.03

Tenofovir:

Distribution among environmental compartments : log Koc: 3.33
Method: OECD Test Guideline 106

Doravirine:

Distribution among environmental compartments : log Koc: 2.86

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Domestic regulation

49 CFR

Not regulated as a dangerous good

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/16/2025
14.0	11/20/2025	58636-00031	Date of first issue: 02/16/2015

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards	:	Reproductive toxicity Specific target organ toxicity (single or repeated exposure) Serious eye damage or eye irritation
-----------------------------	---	---

SARA 313	:	This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.
-----------------	---	---

US State Regulations

Pennsylvania Right To Know

Cellulose, 2-hydroxypropyl methyl ether, acetate hydrogen butanedioate	71138-97-1
Cellulose	9004-34-6
Lamivudine	134678-17-4
Tenofovir	202138-50-9
Doravirine	1338225-97-0
Croscarmellose sodium	74811-65-7

California Permissible Exposure Limits for Chemical Contaminants

Cellulose	9004-34-6
-----------	-----------

The ingredients of this product are reported in the following inventories:

AICS	:	not determined
CA. DSL	:	not determined
IECSC	:	not determined

SECTION 16. OTHER INFORMATION

Further information

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation


Version
14.0

Revision Date:
11/20/2025

SDS Number:
58636-00031

Date of last issue: 06/16/2025
Date of first issue: 02/16/2015

NFPA 704:



HMIS® IV:

HEALTH	*	2
FLAMMABILITY		3
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
CAL PEL	:	California permissible exposure limits for chemical contaminants (Title 8, Article 107)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
OSHA Z-3	:	USA. Occupational Exposure Limits (OSHA) - Table Z-3 Mineral Dusts
ACGIH / TWA	:	8-hour, time-weighted average
CAL PEL / PEL	:	Permissible exposure limit
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA Z-1 / TWA	:	8-hour time weighted average
OSHA Z-3 / TWA	:	8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardization; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06/16/2025
14.0	11/20/2025	58636-00031	Date of first issue: 02/16/2015

50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorization and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 11/20/2025

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8